共 28 条
- [1] Brentuximab Vedotin Plus Doxorubicin, Vinblastine, and Dacarbazine as Frontline Therapy Demonstrates Superior Modified Progression-Free Survival Versus ABVD in Patients With Previously Untreated Stage III or IV Hodgkin Lymphoma: The Phase 3 ECHELON-1 StudyCLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (02) : 7 - 8不详
- [2] Phase 3 study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A plus AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL): Echelon-1 studyJOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Ansell, Stephen MaxtedYounes, AnasConnors, Joseph M.Gallamini, AndreaKim, Won SeogFriedberg, Jonathan W.Feldman, Tatyana A.Collins, GrahamBartlett, NancyWang, JingyuanBrady, KellySachs, JessicaHuebner, DirkHunder, Naomi N. H.Radford, John
- [3] Phase III study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A plus AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL).JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Younes, AnasRadford, JohnAnsell, Stephen MaxtedGallamini, AndreaKim, Wom SeogFeldman, Tatyana A.Hamadani, MehdiChung, JeanenneWang, JingyuanHuebner, DirkConnors, Joseph M.
- [4] Seven-year overall survival analysis from ECHELON-1 study of A plus AVD versus ABVD in patients with previously untreated stage III/IV classical Hodgkin lymphomaJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Ansell, Stephen M.Straus, David J.Connors, Joseph M.Jurczak, WojciechKim, Won-SeogGallamini, AndreaRamchandren, RadhakrishnanFriedberg, Jonathan W.Advani, Ranjana H.Hutchings, MartinEvens, Andrew M.Savage, Kerry J.Eom, Hyeon-SeokFeldman, Tatyana A.Abramson, Jeremy S.Dong, CassieSavani, Bipin N.Zomas, AthanasiosFenton, KeenanRadford, John
- [6] BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY FOR PATIENTS WITH PREVIOUSLY UNTREATED, STAGE III OR IV CLASSICAL HODGKIN LYMPHOMA: 5-YEAR UPDATE OF THE PHASE 3 ECHELON-1 STUDY (NCT01712490)HAEMATOLOGICA, 2021, 106 (10) : 44 - 44Picardi, M.Straus, J.Dlugosz-Danecka, M.Connors, J. M.Illes, A.Lech-Maranda, E.Feldman, T.Smolewski, P.Savage, K. J.Bartlett, N. L.Walewski, J.Ramchandren, R.Zinzani, P. L.Hutchings, M.Munoz, J.Kim, W. S.Advani, R.Ansell, S. M.Gallamini, A.Liu, R.Little, M.Fenton, K.Fanale, M.Radford, J.
- [7] Brentuximab vedotin plus chemotherapy for patients with previously untreated, Stage III or IV classical Hodgkin lymphoma: 5-year update of the phase 3 ECHELON-1 study (NCT01712490)BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 145 - 147Radford, JohnDlugosz-Danecka, MonikaConnors, Joseph M.Illes, ArpadPicardi, MarcoLech-Maranda, EwaFeldman, TatyanaSmolewski, PiotrSavage, Kerry J.Bartlett, Nancy L.Walewski, JanRamchandren, RadhakrishnanZinzani, Pier LuigiHutchings, MartinMunoz, JavierKim, Won SeogAdvani, RanjanaAnsell, Stephen M.Younes, AnasGallamini, AndreaLiu, RachaelLittle, MeredithFenton, KeenanFanale, MichelleStraus, David J.
- [8] Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 studyHEMATOLOGICAL ONCOLOGY, 2021, 39 (02) : 185 - 195Hutchings, MartinRadford, JohnAnsell, Stephen M.Illes, ArpadSureda, AnnaConnors, Joseph M.Sykorova, AliceShibayama, HirohikoAbramson, Jeremy S.Chua, Neil S.Friedberg, Jonathan W.Koren, JanLaCasce, Ann StewardMolina, LysianeEngley, GeraldFenton, KeenanJolin, HinaLiu, RachaelGautam, AshishGallamini, Andrea
- [9] Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 StudyBLOOD, 2020, 136Straus, David J.Dlugosz-Danecka, MonikaConnors, Joseph M.Illes, ArpadPicardi, MarcoLech-Maranda, EwaFeldman, TatyanaSmolewski, PiotrSavage, Kerry J.Bartlett, Nancy L.Walewski, JanRamchandren, RadhakrishnanZinzani, Pier LuigiHutchings, MartinMunoz, JavierKim, Won SeogAdvani, RanjanaAnsell, Stephen M.Younes, AnasGallamini, AndreaLiu, RachaelLittle, MeredithFenton, KeenanFanale, Michelle A.Radford, John A.
- [10] Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 StudyCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S371 - S371Ramchandren, RadhakrishnanDlugosz-Danecka, MonikaConnors, Joseph M.Radford, JohnIlles, ArpadPicardi, MarcoLech-Maranda, EwaFeldman, TatyanaSmolewski, PiotrSavage, Kerry J.Bartlett, Nancy L.Walewski, JanZinzani, Pier LuigiHutchings, MartinMunoz, JavierKim, Won SeogAdvani, RanjanaAnsell, Stephen M.Gallamini, AndreaAlekseev, SergeyLee, Hun JuLiu, RachaelLittle, MeredithFenton, KeenanFanale, MichelleStraus, David J.